Roche Gains PD-1 Edge on Merck With FDA Nod for Subcutaneous Tecentriq

Tecentriq Hybreza, which combines Roche’s Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology, is being touted as the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy.